Physician profile
Salman Malad
NPI 1316936222
$32,938.70
in general payments reported to CMS, 2019-2025
51 companies · $249 in 2025
The $249 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $18.63 · 2021: $280 · 2022: $553 · 2023: $1,677 · 2024: $648 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,214 · Education: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,214.31 |
| Education | $359.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $20,012.36 | 2019-2024 | Reblozyl |
| Pfizer INC. | $8,520.60 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $636.07 | 2019-2024 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $407.08 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Astellas Pharma US INC | $338.74 | 2019-2024 | Xospata, Xtandi, Padcev |
| Novartis Pharmaceuticals Corporation | $326.38 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $276.34 | 2019-2025 | Enhertu, Imfinzi |
| Seagen INC. | $257.86 | 2021-2023 | Tukysa, Adcetris |
| Sanofi-Aventis U.S. LLC | $194.00 | 2019-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $165.47 | 2022-2023 | Imbruvica, Epkinly |
| Sobi, INC | $143.74 | 2023-2025 | |
| Janssen Biotech, INC. | $132.70 | 2022-2025 | Tecvayli, Imbruvica, Rybrevant |
| Genzyme Corporation | $121.09 | 2019-2023 | |
| Lilly USA, LLC | $105.86 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Aveo Pharmaceuticals, INC. | $89.77 | 2023 | Fotivda |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salman Malad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.